Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07007780
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
A Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
Sponsor: Xijing Hospital
Conditions
Triple -Negative Breast Cancer
Interventions
Sacituzumab Tirumotecan
Updated 2 times since 2025 Last updated: Jul 24, 2025 Started: Aug 20, 2025 Primary completion: Aug 31, 2026 Completion: Aug 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07007780, this PHASE2 trial focuses on Triple -Negative Breast Cancer and remains actively recruiting participants. Sponsored by Xijing Hospital, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Aug 2025 — Present [monthly]
Not Yet Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Xijing Hospital
Data source: Xijing Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.